New research finds that heavy alcohol consumption consistently raises cardiovascular risks, while evidence for protective effects of light drinking remains inconclusive.
A secondary analysis of the EMPACT-MI trial, published in Nature Cardiovascular Research, shows that the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin stabilizes kidney function and reduces heart failure hospitalizations in patients who have recently experienced a heart attack.
A phase 3 randomized clinical trial found that cytisinicline, a partial agonist at α4β2 nicotinic acetylcholine receptors, improved smoking cessation rates compared with placebo, with higher abstinence rates and reduced craving over 24 weeks.
The FDA has approved Moderna’s mRESVIA vaccine for adults aged 18 to 59 who are at increased risk for RSV, expanding its indication beyond older adults.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A phase 3 trial of an oral fixed-dose combination of obicetrapib and ezetimibe showed a nearly 50% reduction in LDL cholesterol levels in patients at high risk for heart disease, without added safety concerns.
In a large study across 8 countries, researchers found that ultraprocessed food consumption contributed to thousands of premature deaths annually, with higher risks in countries where these foods dominate diets.
Over 39,000 patients were followed for up to 11 years in a large national study comparing major heart event risks after gastric bypass and sleeve gastrectomy.